Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Palatin/Mallinckrodt LeuTech Is Now NeutroSpec; Second Quarter Approval Predicted

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requested trade name change to avoid confusion with a currently marketed drug, Palatin says. NeutroSpec is pending at FDA for diagnosis of equivocal appendicitis; Palatin completed all BLA amendments in first quarter of 2004.

You may also be interested in...



Palatin/Mallinckrodt Neutrospec Clears FDA; Imaging Agent Available In Mid-August

The radiolabeled monoclonal antibody is approved for diagnosing equivocal appendicitis. Palatin expects to initiate a Phase III trial for diagnosing osteomyelitis by the first quarter of 2005.

Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal

Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.

Topics

UsernamePublicRestriction

Register

PS059540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel